

Barlogie-Salmon Myeloma Committee

Leadership

Chair: Robert Z. Orlowski, MD, PhD
Vice-Chair: Sikander Ailawadhi, MD
Vice-Chair: Jing Christine Ye, MD, MSc
Executive Officer: Susan M. O'Brien, MD
Statisticians: Antje Hoering, PhD
..... Rachael Sexton, MS

Scientific Leadership

Translational Medicine: Brian A. Walker, BSc, PhD
Radiation: Chelsea Camille Pinnix, MD, PhD
Surgery: TBD
Imaging: Saad Z. Usmani, MD, MBA
..... Eric M. Rohren, MD, PhD
Pathology: TBD
Early Therapeutics: Frits van Rhee, MD, PhD

Designates

Digital Engagement: Saad Z. Usmani, MD, MBA
NCORP Representative: Charles S. Kuzma, MD
Veterans Affairs: Thomas R. Chauncey, MD, PhD
Data Coordinators: Sean O'Bryan
..... Hannah Hale
Oncology Research Professionals:
CRA: TBD
Nurses: Deborah A. Shaw, RN
..... Teresa Witcher, BSN, RN
Patient Advocate: Jack Aiello, MS
Pharmaceutical Science: Craig Elg, PharmD
..... Ila M. Saunders, PharmD
Protocol Project Manager: Sharon Palmer
Clinical Trials Program Manager: TBD

Time/Location

Friday, April 8, 2022 7:00 - 9:00 am
Room: Columbia C, Level 3

Agenda

Active Studies

S1803, "Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)." Drs. A. Krishnan and P. Hari. Activated: 6/27/19.

S2005, "A Phase II Randomized Study of Ibrutinib and Rituximab with or Without Venetoclax in Previously Untreated Waldenström's Macroglobulinemia (WM)." Drs. S. Ailawadhi and D. Bhutani. Activated: 6/24/21. Temporarily Closed: 7/16/21. Re-opened to accrual: 10/15/21.

EAA171, "Optimizing Prolonged Treatment in Myeloma Using MRD Assessment (OPTIMUM)." Dr. S. Kumar. Activated: 6/1/21.

EAA173, "Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma." Activated: 4/30/19.

EAA181, "Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial." Activated: 10/27/20.

Closed Studies

S1211, "A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)." Drs. S. Usmani, S. Ailawadhi, and B. Lipe. Activated: 11/9/12. Closed: 6/2/16.

S1702, "A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis." Drs. T. Parker and V. Santhorawala. Activated: 3/08/18; Closed: 9/30/19.

S1304, "A Phase II Randomized Study Comparing Two Doses of Carfilzomib with Dexamethasone for Relapse/Refractory Multiple Myeloma." Dr. S. Ailawadhi. Activated: 10/18/13. Closed: 11/6/15.

S0777, "Frontline Phase III Rev/Dex +/- Vel, no upfront transplant." Dr. B. Durie. Activated: 4/1/18. Closed: 2/2/12.

S0120, "A prospective Observational Biologic Study of Asymptomatic Patients with Monoclonal Gammopathy and Plasmaproliferative Disorders." Dr. M. Dhodapkar. Activated: 6/1/02. Closed: 4/1/11.

CTN 0702, "Single Autologous Transplant with or without RVD Consolidation versus Tandem Trans-plant and Maintenance Therapy." Dr. G. Somlo. Activated: 2/15/11. Closed: 11/15/13.

A061402, "Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone after Radiation Therapy in Treating Patients with Solitary Plasmacytoma of Bone." Dr. A. Kuman Mahindra. Activated: 12/23/15. Closed: 8/15/19.

Tweeting the Meeting

Twitter is a major venue you can use to get out word about what you learn at the group meeting.

@SWOG has more than 11,000 followers and can amplify your message.

Follow SWOG
at twitter.com/SWOG

With your group
meeting tweets ...

tag your @SWOG friends

use the hashtag
#SWOGonc



Barlogie-Salmon Myeloma Committee

E1A11, "Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Le-nalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDUR-ANCE)." Drs. S. Kumar, A. Cohen, and J. Zonder. Activated: 11/22/13. Closed: 1/29/19.

E3A06 (was S0909), "High-risk AMM – Revlimid." Dr. M. Dhodopkar. Activated: 1/17/11. Closed: 7/14/17.

A061402, "Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone after Radiation Therapy in Treating Patients with Solitary Plasmacytoma of Bone." Dr. A. Kumar Mahindra. Activated: 12/23/15. Closed: 8/15/19.

E1A11, "Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Le-nalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDUR-ANCE)." Drs. S. Kumar, A. Cohen and J. Zonder. Activated: 11/22/13. Closed: 1/29/19.

Proposed Studies

S2209, "A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Upfront Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd)." Drs. S. Al-lawadhi, C. Ye, and A. Gowin.

S2213, "Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCD) Induction Followed by Autologous Stem Cell Transplant or D-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis." Dr. P. Hagen

S1911, "Phase III Study of Optimal Induction Therapy for Newly Diagnosed High-Risk Multiple Myeloma (HRMM) RVD Dara +/- xx." Dr. B. Lipe.

Barlogie-Salmon Myeloma Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

	S1803	A061202	EAA173	EAA181
Ascension Providence Hospitals - Southfield	1	1	-	-
Banner University Medical Center - Tucson	6	-	-	-
Boston Medical Center	5	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	10	-	2	-
Cancer Research of Wisconsin and Northern Michigan Consortium	3	-	-	-
Cedars-Sinai Medical Center	5	-	-	-
City of Hope Comprehensive Cancer Center	66	-	-	-
Columbus NCI Community Oncology Research Program	7	-	-	-
CommonSpirit Health Research Institute	3	-	-	-
Dayton NCI Community Oncology Research Program	4	-	-	-
Duke University - Duke Cancer Institute LAPS	1	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	4	-
Georgia NCI Community Oncology Research Program	10	-	-	-
Gulf South Minority Underserved NCORP	2	-	-	-
Heartland Cancer Research NCORP	13	-	-	-
Henry Ford Hospital	-	1	-	-
Kaiser Permanente NCI Community Oncology Research Program	31	-	-	-
Lahey Hospital and Medical Center	3	-	-	-
Loyola University Medical Center	16	-	2	-
Medical University of South Carolina Minority Underserved NCORP	18	-	1	-
Moffitt Cancer Center	30	-	-	-
Montana Cancer Consortium NCORP	3	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	1	-
New Mexico Minority Underserved NCORP	6	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	4	-	-	-
Oregon Health and Science University	11	-	2	2
Pacific Cancer Research Consortium NCORP	5	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	3	-	-	-
UC Davis Comprehensive Cancer Center LAPS	15	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	2	-	-	-
University of Arkansas for Medical Sciences	-	-	-	1
University of Kansas Cancer Center - MCA Rural MU NCORP	18	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	7	-	-	-
University of Oklahoma Health Sciences Center LAPS	1	-	-	-
University of Rochester LAPS	11	-	-	-
University of Texas Health Science Center at San Antonio	11	-	-	-
University of Texas MD Anderson Cancer Center LAPS	17	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	10	-	2	-
Upstate Carolina Consortium Community Oncology Research Program	3	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	9	-	-	-
Wisconsin NCI Community Oncology Research Program	13	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	2	-
ALLIANCE	113	-	-	-
ECOG-ACRIN	92	-	-	-
NRG	56	-	-	-
Total	644	2	16	3